Get started

Financials · MRVI

Maravai LifeSciences Holdings Inc. (MRVI) financials

For the twelve months ended Sep 30, 2026, Maravai LifeSciences Holdings Inc. reported $213.00M of revenue and -$65.67M of net income.

Revenue, TTM
$213.00M
Revenue growth, YoY
+10.7%
Net income, TTM
-$65.67M
Net margin
-30.8%
Free cash flow, TTM
-$13.27M
EPS, diluted, TTM
-$0.43
Cash
$73.02M
Total debt
$147.18M
P/S
9.79
Market cap
$2.08B
Annual revenue$185.74M
FY2019FY2025
Annual net income-$130.77M
FY2019FY2025
Annual free cash flow-$70.72M
FY2019FY2025

MRVI revenue and earnings growth

MRVI revenueQ3 2026$45.85M

Quarter YoY
+10.1%
QoQ
-10.9%
FY YoY
-28.3%
5Y CAGR
-8.1%

MRVI revenue was $45.85M in fiscal Q3 2026 (ended Sep 30, 2026), up 10.1% from a year earlier and down 10.9% from the prior quarter. For the full fiscal 2025 it was $185.74M, down 28.3% from fiscal 2024. Compound annual growth was -8.1% over 5 years. It rose in 3 of the last 6 fiscal years.

MRVI net incomeQ3 2026-$13.84M

MRVI net income was -$13.84M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$25.56M a year earlier. For the full fiscal 2025 it was -$130.77M, compared with -$144.85M in fiscal 2024.

MRVI EPSQ3 2026-$0.09

MRVI diluted EPS was -$0.09 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.18 a year earlier. For the full fiscal 2025 it was -$0.90, compared with -$1.05 in fiscal 2024.

MRVI free cash flowQ3 2026$4.49M

QoQ
+24.0%

MRVI free cash flow was $4.49M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$18.08M a year earlier and up 24.0% from the prior quarter. For the full fiscal 2025 it was -$70.72M, compared with -$22.19M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$185.74M$259.19M$288.94M$883.00M$799.24M$284.10M$143.14M
Cost of revenue$151.75M$150.88M$148.74M$168.96M$140.56M$79.65M$66.85M
Gross profit$33.99M$108.31M$140.20M$714.04M$658.68M$204.45M$76.29M
Research and development$17.40M$19.22M$17.28M$18.37M$15.22M$9.30M$3.63M
Selling, general and admin$145.12M$161.77M$151.39M$129.26M$100.06M$94.25M$48.35M
Operating income-$215.27M-$235.62M-$31.65M$574.22M$554.64M$119.90M$23.99M
Interest expense$26.99M$47.70M$45.89M$20.41M$30.26M$30.74M$29.96M
Pre-tax income-$234.97M-$261.48M$617.74M$551.47M$530.76M$81.70M-$5.85M
Income tax-$4.21M-$1.86M$756.11M$60.81M$61.52M$2.88M-$652.0K
Net income-$130.77M-$144.85M-$119.03M$220.21M$182.04M$88.97M-$4.47M
EPS, basic-$0.90-$1.05-$0.90$1.67$1.59$7.43-$0.03
EPS, diluted-$0.90-$1.05-$0.90$1.67$1.56$2.36-$0.03
Diluted shares144.4M137.9M131.9M255.3M257.8M28.9M253.9M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$216.89M$322.40M$574.96M$632.14M$551.27M$236.18M$24.70M
Receivables$25.50M$38.52M$54.60M$138.62M$117.51M$51.02M-
Inventory$40.49M$50.08M$51.40M$43.15M$51.56M$33.30M-
Current assets$296.25M$429.15M$699.91M$847.90M$740.04M$331.60M-
Goodwill$129.43M$159.88M$326.03M$283.67M$152.77M$224.28M-
Total assets$770.58M$1.01B$1.49B$2.28B$1.92B$1.27B-
Current liabilities$44.92M$56.97M$87.47M$110.14M$93.78M$130.78M-
Short-term debt$5.44M$5.44M$5.44M$5.44M$6.00M$6.00M-
Long-term debt$286.33M$290.49M$518.71M$522.00M$524.59M$528.61M-
Total debt$291.77M$295.93M$524.15M$527.44M$530.59M$534.61M-
Total liabilities$397.87M$431.04M$697.57M$1.38B$1.37B$1.12B-
Shareholders' equity$212.38M$577.21M$789.88M$905.24M$545.36M$154.75M$144.63M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$57.57M$7.46M$126.22M$535.98M$368.57M$152.19M$24.11M
Capital expenditures$13.15M$29.66M$65.55M$17.09M$14.85M$25.41M$17.15M
Free cash flow-$70.72M-$22.19M$60.67M$518.89M$353.72M$126.78M$6.97M
Investing cash flow-$31.41M-$24.32M-$122.31M-$267.61M$105.66M$6.07M-$17.15M
Financing cash flow-$16.50M-$235.71M-$61.09M-$187.50M-$159.05M$53.21M-$4.17M
Share repurchases---$0$0$33.66M$0
Stock-based compensation$30.17M$49.41M$34.59M$18.67M$10.46M$24.63M$1.68M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY-28.3%-10.3%-67.3%10.5%181.3%98.5%-
Net income growth, YoY---21.0%104.6%--
EPS growth, YoY---7.1%---
Gross margin18.3%41.8%48.5%80.9%82.4%72.0%53.3%
Operating margin-115.9%-90.9%-11.0%65.0%69.4%42.2%16.8%
Net margin-70.4%-55.9%-41.2%24.9%22.8%31.3%-3.1%
Free cash flow margin-38.1%-8.6%21.0%58.8%44.3%44.6%4.9%
Return on equity-61.6%-25.1%-15.1%24.3%33.4%57.5%-3.1%
Return on assets-17.0%-14.4%-8.0%9.6%9.5%7.0%-
Current ratio6.607.538.007.707.892.54-
Debt to equity1.370.510.660.580.973.45-

Source: XBRL data Maravai LifeSciences Holdings Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MRVI peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MRVI$213.00M+10.7%-$65.67M-30.8%$2.08B
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

MRVI FAQ

9 questions
  • What is MRVI revenue?
    Maravai LifeSciences Holdings Inc. (MRVI) reported $213.00M of revenue for the twelve months ended Sep 30, 2026. That is up 10.7% from the year before. Revenue for fiscal 2025 was $185.74M.
  • Is MRVI profitable?
    No. Maravai LifeSciences Holdings Inc. reported a net loss of $65.67M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does MRVI have?
    Maravai LifeSciences Holdings Inc. reported $73.02M in cash and cash equivalents and $147.18M of debt on its most recent balance sheet in SEC filings.
  • How fast is MRVI revenue growing?
    Maravai LifeSciences Holdings Inc.'s revenue changed -28.3% in fiscal 2025, to $185.74M. Its compound annual growth rate was -8.1% over 5 years.
  • What is MRVI gross margin?
    Maravai LifeSciences Holdings Inc.'s gross profit was $83.39M on $213.00M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 39.1%.
  • What is MRVI free cash flow?
    Maravai LifeSciences Holdings Inc. generated -$13.27M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$5.10M less capital expenditures.
  • What is MRVI earnings per share?
    Diluted earnings per share were -$0.43 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did MRVI last report financial results?
    The latest statements here come from Maravai LifeSciences Holdings Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this MRVI financial data come from?
    Quantisnow builds these statements from the structured XBRL data Maravai LifeSciences Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.